December 01, 2004

Hungarian drug company working on new schizophrenia target

In a sign of more new therapies that may make it to market to help people who have schizophrenia, Hungarian drugmaker Richter Gedeon and the USA's Forest Laboratories have signed a collaborative agreement for the former's atypical antipsychotic identified as "RGH-188" and related compounds.

Forest will have exclusive rights to the product in the USA and Canada while Richter Gedeon will retain rights in the rest of the world. Both parties will be involved in the development of the product and will jointly fund such activities.

The Drug, called "RGH-188" (during pre-release status),is a novel, orally-active dopamine D2/D3 antagonist, is currently undergoing Phase I trials in the UK and has potential utility for the treatment of schizophrenia and bipolar mania, as well as other psychiatric conditions.


Post a comment

Please enter this code to enable your comment -
Remember Me?
(you may use HTML tags for style)
* indicates required